{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T20:54:49Z","timestamp":1789419289563,"version":"build-2803163510"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T00:00:00Z","timestamp":1787702400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T00:00:00Z","timestamp":1787702400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Res."],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s44313-026-00165-y","type":"journal-article","created":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T09:00:47Z","timestamp":1787734847000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Frontline daratumumab, lenalidomide, and dexamethasone in patients older than 80\u00a0years with newly diagnosed multiple myeloma: treatment durability, infectious complications, and nutritional vulnerability"],"prefix":"10.1007","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-2707-8472","authenticated-orcid":false,"given":"Yuichi","family":"Horigome","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Ehata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriyuki","family":"Tadera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei","family":"Hayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotoshi","family":"Kamata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Miyazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,26]]},"reference":[{"issue":"22","key":"165_CR1","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1056\/NEJMoa1817249","volume":"380","author":"T Facon","year":"2019","unstructured":"Facon T, Kumar S, Plesner T, Orlowski RZ, Moreau P, Bahlis N, et al. Daratumumab plus lenalidomide and dexamethasone for untreated myeloma. N Engl J Med. 2019;380(22):2104\u201315. https:\/\/doi.org\/10.1056\/NEJMoa1817249.","journal-title":"N Engl J Med"},{"issue":"4","key":"165_CR2","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1038\/s41375-024-02505-2","volume":"39","author":"T Facon","year":"2025","unstructured":"Facon T, Moreau P, Weisel K, Goldschmidt H, Usmani SZ, Chari A, et al. Daratumumab\/lenalidomide\/dexamethasone in transplant-ineligible newly diagnosed myeloma: MAIA long-term outcomes. Leukemia. 2025;39(4):942\u201350. https:\/\/doi.org\/10.1038\/s41375-024-02505-2.","journal-title":"Leukemia"},{"issue":"4","key":"165_CR3","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1038\/s41375-021-01488-8","volume":"36","author":"T Facon","year":"2022","unstructured":"Facon T, Cook G, Usmani SZ, Hulin C, Kumar S, Plesner T, et al. Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA. Leukemia. 2022;36(4):1066\u201377. https:\/\/doi.org\/10.1038\/s41375-021-01488-8.","journal-title":"Leukemia"},{"issue":"1","key":"165_CR4","doi-asserted-by":"publisher","first-page":"e32","DOI":"10.3324\/haematol.2017.173617","volume":"103","author":"F Panitsas","year":"2018","unstructured":"Panitsas F, Kothari J, Vallance G, Djebbari F, Ferguson L, Sultanova M, et al. Treat or palliate: outcomes of very elderly myeloma patients. Haematologica. 2018;103(1):e32\u20134. https:\/\/doi.org\/10.3324\/haematol.2017.173617.","journal-title":"Haematologica"},{"issue":"1","key":"165_CR5","doi-asserted-by":"publisher","first-page":"163","DOI":"10.3324\/haematol.2024.285645","volume":"110","author":"CH Blimark","year":"2008","unstructured":"Blimark CH, Carlson K, Day C, Einarsdottir S, Juliusson G, Karma M, et al. Risk of infections in multiple myeloma. A population-based study on 8,672 multiple myeloma patients diagnosed 2008-2021 from the Swedish Myeloma Registry. Haematologica. 2008;110(1):163\u201372. https:\/\/doi.org\/10.3324\/haematol.2024.285645.","journal-title":"Haematologica"},{"issue":"13","key":"165_CR6","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.1182\/blood-2014-12-615187","volume":"125","author":"A Palumbo","year":"2015","unstructured":"Palumbo A, Bringhen S, Mateos MV, Larocca A, Facon T, Kumar SK, et al. Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. Blood. 2015;125(13):2068\u201374. https:\/\/doi.org\/10.1182\/blood-2014-12-615187.","journal-title":"Blood"},{"issue":"1","key":"165_CR7","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1038\/s41375-019-0539-0","volume":"34","author":"T Facon","year":"2020","unstructured":"Facon T, Dimopoulos MA, Meuleman N, Belch A, Mohty M, Chen WM, et al. A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial. Leukemia. 2020;34(1):224\u201333. https:\/\/doi.org\/10.1038\/s41375-019-0539-0.","journal-title":"Leukemia"},{"key":"165_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17172904","author":"P Sobrini-Morillo","year":"2025","unstructured":"Sobrini-Morillo P, Corral-Tuesta C, S\u00e1nchez-Castellano C, Guti\u00e9rrez-Blanco T, Palomo-Rumschisky P, \u00c1lvarez-Pinheiro CG, et al. Comprehensive geriatric assessment of older patients with multiple myeloma: a prospective observational study. Cancers (Basel). 2025. https:\/\/doi.org\/10.3390\/cancers17172904.","journal-title":"Cancers (Basel)"},{"key":"165_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1545096","volume":"15","author":"Y Nie","year":"2025","unstructured":"Nie Y, Zhang Z, Tang X. Prognostic and clinicopathological value of prognostic nutritional index in patients with multiple myeloma: a meta-analysis. Front Oncol. 2025;15:1545096. https:\/\/doi.org\/10.3389\/fonc.2025.1545096.","journal-title":"Front Oncol"},{"key":"165_CR10","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyag040","author":"K Suzuki","year":"2026","unstructured":"Suzuki K, Gunji T, Nagao R, Uryu H, Yokoyama H, Katsube A, et al. Geriatric nutritional risk index predicts 10-year survival in patients with multiple myeloma. Jpn J Clin Oncol. 2026. https:\/\/doi.org\/10.1093\/jjco\/hyag040.","journal-title":"Jpn J Clin Oncol"},{"issue":"9","key":"165_CR11","first-page":"1001","volume":"85","author":"T Onodera","year":"1984","unstructured":"Onodera T, Goseki N, Kosaki G. Prognostic nutritional index in gastrointestinal surgery of malnourished cancer patients. Nihon Geka Gakkai Zasshi. 1984;85(9):1001\u20135.","journal-title":"Nihon Geka Gakkai Zasshi"},{"issue":"4","key":"165_CR12","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1093\/ajcn\/82.4.777","volume":"82","author":"O Bouillanne","year":"2005","unstructured":"Bouillanne O, Morineau G, Dupont C, Coulombel I, Vincent JP, Nicolis I, et al. Geriatric nutritional risk index: a new index for evaluating at-risk elderly medical patients. Am J Clin Nutr. 2005;82(4):777\u201383. https:\/\/doi.org\/10.1093\/ajcn\/82.4.777.","journal-title":"Am J Clin Nutr"},{"issue":"8","key":"165_CR13","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/s1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17(8):e328\u201346. https:\/\/doi.org\/10.1016\/s1470-2045(16)30206-6.","journal-title":"Lancet Oncol"},{"issue":"3","key":"165_CR14","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y. Investigation of the freely available easy-to-use software \u201cEZR\u201d for medical statistics. Bone Marrow Transplant. 2013;48(3):452\u20138. https:\/\/doi.org\/10.1038\/bmt.2012.244.","journal-title":"Bone Marrow Transplant"},{"key":"165_CR15","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2025019323","author":"NJ Bahlis","year":"2026","unstructured":"Bahlis NJ, Facon T, San-Miguel JF, Usmani SZ, Dimopoulos MA, Moreau P, et al. Infections in patients receiving daratumumab for newly diagnosed multiple myeloma: a pooled analysis of MAIA and ALCYONE. Blood Adv. 2026. https:\/\/doi.org\/10.1182\/bloodadvances.2025019323.","journal-title":"Blood Adv"},{"issue":"1","key":"165_CR16","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s44313-025-00102-5","volume":"60","author":"J Jung","year":"2025","unstructured":"Jung J. Treatment of transplant-ineligible multiple myeloma. Blood Res. 2025;60(1):53. https:\/\/doi.org\/10.1007\/s44313-025-00102-5.","journal-title":"Blood Res"},{"issue":"10","key":"165_CR17","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1016\/s1470-2045(25)00280-3","volume":"26","author":"S Manier","year":"2025","unstructured":"Manier S, Lambert J, Hulin C, Macro M, Laribi K, Araujo C, et al. Safety and efficacy of a dexamethasone-sparing regimen with daratumumab and lenalidomide in patients with frailty and newly diagnosed multiple myeloma (IFM2017-03): a phase 3, open-label, multicentre, randomised, controlled trial. Lancet Oncol. 2025;26(10):1323\u201333. https:\/\/doi.org\/10.1016\/s1470-2045(25)00280-3.","journal-title":"Lancet Oncol"},{"issue":"10","key":"165_CR18","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1200\/jco-25-02587","volume":"44","author":"LK Hicks","year":"2026","unstructured":"Hicks LK, Messersmith HJ, Al Hadidi S, Banerjee R, Derman BA, Kumar S, et al. Treatment of multiple myeloma: ASCO-Ontario Health (Cancer Care Ontario) living guideline. J Clin Oncol. 2026;44(10):914\u201341. https:\/\/doi.org\/10.1200\/jco-25-02587.","journal-title":"J Clin Oncol"},{"issue":"10","key":"165_CR19","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1038\/s41430-022-01120-7","volume":"76","author":"Y Xiao","year":"2022","unstructured":"Xiao Y, Wei G, Ma M, Liu D, Chen P, Quan H, et al. Association among prognostic nutritional index, post-operative infection and prognosis of stage II\/III gastric cancer patients following radical gastrectomy. Eur J Clin Nutr. 2022;76(10):1449\u201356. https:\/\/doi.org\/10.1038\/s41430-022-01120-7.","journal-title":"Eur J Clin Nutr"},{"key":"165_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/fnut.2025.1660457","volume":"12","author":"Z Ding","year":"2025","unstructured":"Ding Z, He Y, Guo X, Feng R, Ren G, Deng L, et al. Prognostic nutritional index and mortality in pneumonia: a retrospective cohort study in China. Front Nutr. 2025;12:1660457. https:\/\/doi.org\/10.3389\/fnut.2025.1660457.","journal-title":"Front Nutr"}],"updated-by":[{"DOI":"10.1007\/s44313-026-00178-7","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T00:00:00Z","timestamp":1789344000000}}],"container-title":["Blood Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s44313-026-00165-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s44313-026-00165-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s44313-026-00165-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T09:20:03Z","timestamp":1789377603000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s44313-026-00165-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,26]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["165"],"URL":"https:\/\/doi.org\/10.1007\/s44313-026-00165-y","relation":{},"ISSN":["2287-979X","2288-0011"],"issn-type":[{"value":"2287-979X","type":"print"},{"value":"2288-0011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,26]]},"assertion":[{"value":"17 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2026","order":6,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":7,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s44313-026-00178-7","URL":"https:\/\/doi.org\/10.1007\/s44313-026-00178-7","order":9,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"YH received honoraria from Janssen, Bristol Myers Squibb, Sanofi, Takeda, Ono Pharmaceutical, CSL Behring, and Pfizer. NT received honoraria from Sanofi and Daiichi Sankyo. KH received honoraria from Bristol Myers Squibb. HK received honoraria from Asahi Kasei, Novartis, Sanofi, Janssen, Bristol Myers Squibb, BeOne Medicines, AbbVie, Ono Pharmaceutical, Takeda, and Daiichi Sankyo. TS received honoraria from Janssen, Bristol Myers Squibb, Sanofi, Takeda, and Ono Pharmaceutical. KM received honoraria from Sanofi and Takeda. KE declares no competing financial interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"47"}}